Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials.

The overall moderate evidence from the RCTs confirmed the significantly short-term and middle-term efficacy of BPs on periprosthetic bone loss after joint arthroplasty. To obtain a better efficacy, the second and the third generation of BPs may be the choice. Lin T, Yan SG, Cai XZ, Ying ZM. Osteoporos Int. 2011 Sep 20. [Epub ahead of print] PMID: 21932113